{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-056596","form_type":"8-K","ticker":"JSPR","cik":"0001788028","company_name":"Jasper Therapeutics, Inc.","filed_at":"2026-05-14T20:05:17+00:00","discovered_at":"2026-05-14T20:07:00.245507+00:00","generated_at":"2026-05-14T21:01:59.073297+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Jasper Therapeutics Q1 net loss $1.2M; refiles Phase 2b protocol for briquilimab in CSU","bullets":["Cash and equivalents of $14.1M as of March 31, 2026, with $5.8M R&D and $5.1M G&A expenses.","Refiled Phase 2b protocol with FDA for briquilimab in chronic spontaneous urticaria; seeks funding to start H2 2026.","Jeet Mahal appointed CEO to lead next phase of clinical growth.","Positive clinical data: 67% of BEACON patients achieved complete response at 12 weeks; 75% in open-label achieved well-controlled disease.","Median follow-up >200 days; KIT-related AEs low-grade and resolved on study."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-056596","json":"https://secwatch.observer/filing/0001213900-26-056596.json","markdown":"https://secwatch.observer/filing/0001213900-26-056596.md","text":"https://secwatch.observer/filing/0001213900-26-056596.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1788028/000121390026056596/0001213900-26-056596-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1788028/000121390026056596/ea0290792-8k_jasper.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T21:01:59.073297+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a3b4ef302849281e8c1733daa384c1b127024e91","claim":"Jasper Therapeutics, Inc. reported the quarter ended March 31, 2026 results: net income net loss of $1.2 million, EPS basic and diluted net loss per share attributable to common stockholders of $0.04.","evidence_excerpt":"Jasper reported a net loss of $1.2 million, or basic and diluted net loss per share attributable to common stockholders of $0.04 for the three months ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390026056596/0001213900-26-056596-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2026"},{"label":"Net income","value":"net loss of $1.2 million"},{"label":"EPS","value":"basic and diluted net loss per share attributable to common stockholders of $0.04"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}